AKBA - Akebia Ther - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

AKBA is currently covered by 2 analysts with an average price target of $7.02. This is a potential upside of $4.41 (168.97%) from yesterday's end of day stock price of $2.61.

Akebia Ther's activity chart (see below) currently has 70 price targets and 73 ratings on display. The stock rating distribution of AKBA is 27.78% HOLD and 72.22% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 47.91% with an average time for these price targets to be met of 287.55 days.

Highest price target for AKBA is $7.5, Lowest price target is $7.5, average price target is $5.75.

Most recent stock forecast was given by ED ARCE from HC WAINWRIGHT on 04-Apr-2025. First documented stock forecast 14-May-2015.

Currently out of the existing stock ratings of AKBA, 5 are a HOLD (27.78%), 13 are a BUY (72.22%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$7.5

$4.95 (194.12%)

$7.5

1 months 13 days ago
(04-Apr-2025)

12/29 (41.38%)

$5.73 (323.73%)

276

Buy

$4

$1.45 (56.86%)

$2

1 years 11 months 16 days ago
(31-May-2023)

1/12 (8.33%)

$2.96 (284.62%)

721

Buy

$1

$-1.14 (-53.27%)

$8

3 years 1 months 15 days ago
(01-Apr-2022)

1/2 (50%)

$0.33 (49.25%)

311

Buy

$6

3 years 1 months 15 days ago
(31-Mar-2022)

0/3 (0%)

$3.28 (120.59%)

Buy

$7

3 years 1 months 15 days ago
(31-Mar-2022)

3/6 (50%)

$5.37 (107.92%)

411

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is AKBA (Akebia Ther) average time for price targets to be met?

On average it took 287.55 days on average for the stock forecasts to be realized with a an average price target met ratio 47.91

Which analyst has the current highest performing score on AKBA (Akebia Ther) with a proven track record?

DIFEI YANG

Which analyst has the most public recommendations on AKBA (Akebia Ther)?

Difei Yang has 22 price targets and 20 ratings on AKBA

Which analyst is the currently most bullish on AKBA (Akebia Ther)?

Jonathan Aschoff with highest potential upside - $24.86

Which analyst is the currently most reserved on AKBA (Akebia Ther)?

Alethia Young with lowest potential downside - -$1.14

Akebia Ther in the News

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) — Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted eight newly-hired employees options to purchase an aggregate of 148,000 shares of Akebia’s common stock on April 30, 2025. The options were granted as an...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?